Human Microbiology Institute commits expertise and assets to the fight against COVID-19 pandemic
New York, March 19, 2020 — Today, Human Microbiology Institute (HMI) announced that it accelerates the development of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. HMI brings a range of breakthrough resources and expertise needed to identify novel therapeutic targets within SARS-VoC-2 for the new solutions to the pandemic
As co-founder of HMI, Dr. George Tetz, said “We feel a deep responsibility to find new therapeutic solutions that will be available for the whole life sciences industry and patients. Our latest discoveries that soon will be publically available and open can accelerate solutions to this pandemic”.
HMI clams to bring a better targets that might not only potentiate therapeutic effects of existing drugs and diagnostic tests but also bring brand new therapeutic targets for therapies and vaccines.
Dr. George Tetz said that “our ultimate goal is not only to flatten the curve of this pandemic, but to uncover viral particularities that will bring breakthrough therapies”.